Précédent|Prochain

Progrès dans les méthodes d'évaluation et les études d'efficacité du traitement anti-ostéoporose par la médecine chinoise basées sur le modèle du poisson zèbre

  • role： First author第一作者
  • Affiliation：

    Xiangyang No.1 People′s Hospital， Hubei Universi ty of Medicine， Xiangyang 441000，China

    Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City， Xiangyang No.1 People's Hospital， Hubei University of Medicine， Xiangyang 441000，China

  • Email：15797180001@163.com
  • Introduction：王恒鸿，在读硕士，从事骨质疏松相关疾病的诊断与治疗研究，E-mail：15797180001@163.com
WANG Henghong12,  
  • Affiliation：

    Xiangyang No.1 People′s Hospital， Hubei Universi ty of Medicine， Xiangyang 441000，China

    Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City， Xiangyang No.1 People's Hospital， Hubei University of Medicine， Xiangyang 441000，China

FAN Xinyu12,  
  • Affiliation：

    Xiangyang No.1 People′s Hospital， Hubei Universi ty of Medicine， Xiangyang 441000，China

    Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City， Xiangyang No.1 People's Hospital， Hubei University of Medicine， Xiangyang 441000，China

GAO Yihan12,  
  • Affiliation：

    Xiangyang No.1 People′s Hospital， Hubei Universi ty of Medicine， Xiangyang 441000，China

    Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City， Xiangyang No.1 People's Hospital， Hubei University of Medicine， Xiangyang 441000，China

LUO Zhilue12,  
  • Affiliation：

    Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City， Xiangyang No.1 People's Hospital， Hubei University of Medicine， Xiangyang 441000，China

DUAN Peng2,  
  • role： Corresponding author通信作者
  • Affiliation：

    Xiangyang No.1 People′s Hospital， Hubei Universi ty of Medicine， Xiangyang 441000，China

  • Email：yfzhou0506@163.com
  • Introduction：周云烽，博士，主治医师，从事运动损伤及骨质疏松相关疾病的诊断与治疗研究，E-mail：yfzhou0506@163.com
ZHOU Yunfeng1*

résumé

L'ostéoporose (OP) est une maladie métabolique systémique fortement liée à l'âge. En raison du problème croissant du vieillissement de la population, l'incidence de l'OP augmente chaque année. Actuellement, les méthodes de traitement de l'OP présentent de nombreuses lacunes, tandis que la médecine traditionnelle chinoise de notre pays possède une longue histoire et une grande diversité d'espèces. Ces dernières années, de plus en plus de recherches sur les effets anti-OP des médicaments chinois ont émergé, pouvant offrir des stratégies alternatives sûres et efficaces pour le traitement de l'OP. Le poisson zèbre, en raison de sa grande transparence optique et de sa forte homologie avec les gènes humains, est largement utilisé comme modèle animal dans la recherche des mécanismes des maladies osseuses humaines et le criblage des médicaments. Les revues précédentes ont rarement abordé les voies de signalisation impliquées dans le traitement anti-OP par la médecine chinoise, les méthodes comparatives des modèles OP chez le poisson zèbre et leur comparaison avec les modèles animaux traditionnels. Cet article passe en revue les recherches sur la médecine chinoise anti-OP utilisant le modèle du poisson zèbre, résume les méthodes d'évaluation expérimentale impliquées, analyse l'état actuel des recherches sur le traitement de l'OP par la médecine chinoise avec ce modèle, résumé les mécanismes d'action et les voies de signalisation concernées, compare et synthétise les différentes méthodes de modélisation OP chez le poisson zèbre, et compare les avantages et inconvénients du poisson zèbre par rapport aux modèles animaux traditionnels, dans le but de fournir des références méthodologiques pour la recherche sur les maladies osseuses utilisant le modèle du poisson zèbre et comme référence pour les études sur les mécanismes d'action de la médecine chinoise dans le traitement de l'OP et le développement de nouveaux médicaments.

mots-clés

ostéoporose; poisson zèbre; médecine chinoise; voies de signalisation; criblage des médicaments

References

  1. 1.
    CHEN S，XU X，GONG H，et al.Global epidemiological features and impact of osteosarcopenia：A comprehensive meta-analysis and systematic review［J］.J Cachexia Sarcopenia Muscle，2024，15（1）：8-20.
  2. 2.
    QIU X P， LIU K J，LIN Y H，et al.Research progress on epidemiology，management，and prevention of osteoporosis［J］.Shandong Med J，2023，63（21）：107-111.
  3. 3.
    ODÉN A，MCCLOSKEY E V，KANIS J A，et al.Burden of high fracture probability worldwide：Secular increases 2010-2040［J］.Osteoporos Int，2015，26（9）：2243-2248.
  4. 4.
    BURGE R，DAWSON-HUGHES B，SOLOMON D H，et al.Incidence and economic burden of osteoporosis-related fractures in the United States，2005-2025［J］.J Bone Miner Res，2007，22（3）：465-475.
  5. 5.
    KHOSLA S.Personalising osteoporosis treatment for patients at high risk of fracture［J］.Lancet Diabetes Endocrinol，2019，7（10）：739-741.
  6. 6.
    REID I R，BILLINGTON E O.Drug therapy for osteoporosis in older adults［J］.Lancet，2022，399（10329）：1080-1092.
  7. 7.
    REID I R.A broader strategy for osteoporosis interventions［J］.Nat Rev Endocrinol，2020，16（6）：333-339.
  8. 8.
    ZHAO Z，CAI Z，CHEN A，et al.Application of metabolomics in osteoporosis research［J］.Front Endocrinol （Lausanne），2022，13：993253.
  9. 9.
    KWON R Y，WATSON C J，KARASIK D.Using zebrafish to study skeletal genomics［J］.Bone，2019，126：37-50.
  10. 10.
    BUSSE B，GALLOWAY J L，GRAY R S，et al.Zebrafish：An emerging model for orthopedic research［J］.J Orthop Res，2020，38（5）：925-936.
  11. 11.
    SUR A，WANG Y，CAPAR P，et al.Single-cell analysis of shared signatures and transcriptional diversity during zebrafish development［J］.Dev Cell，2023，58（24）：3028-3047.
  12. 12.
    TZUNG K W，LALONDE R L，PRUMMEL K D，et al.A median fin derived from the lateral plate mesoderm and the origin of paired fins［J］.Nature，2023，618（7965）：543-549.
  13. 13.
    HAWKINS M B，HENKE K，HARRIS M P.Latent developmental potential to form limb-like skeletal structures in zebrafish［J］.Cell，2021，184（4）：899-911.
  14. 14.
    DERYNCK R.Skeletal development in the zebrafish［J］.Nat Genet，1999，23（4）：379.
  15. 15.
    ZHAO C，ZHAI Y，GENG R，et al.Genetic analysis of activin/inhibin β subunits in zebrafish development and reproduction［J］.PLoS Genet，2022，18（12）：e1010523.
  16. 16.
    CARNOVALI M，RAMONI G，BANFI G，et al.Herbal preparation （bromelain，papain，curcuma，black pepper） enhances mineralization and reduces glucocorticoid-induced osteoporosis in zebrafish［J］.Antioxidants （Basel），2021，10（12）：1987.
  17. 17.
    ITO T，ANDO H，HANDA H.Teratogenic effects of thalidomide：Molecular mechanisms［J］.Cell Mol Life Sci，2011，68（9）：1569-1579.
  18. 18.
    VARGESSON N，HOOPER G，GIDDINS G，et al.Thalidomide upper limb embryopathy-pathogenesis，past and present management and future considerations［J］.J Hand Surg Eur Vol，2023，48（8）：699-709.
  19. 19.
    HUGHES A J，SPELKE D P，XU Z，et al.Single-cell western blotting［J］.Nat Methods，2014，11（7）：749-755.
  20. 20.
    DU S J，FRENKEL V，KINDSCHI G，et al.Visualizing normal and defective bone development in zebrafish embryos using the fluorescent chromophore calcein［J］.Dev Biol，2001，238（2）：239-246.
  21. 21.
    CHEN J R，LAI Y H，TSAI J J，et al.Live fluorescent staining platform for drug-screening and mechanism-analysis in zebrafish for bone mineralization［J］.Molecules，2017，22（12）：2068.
  22. 22.
    AIDO M，KERSCHNITZKI M，HOERTH R，et al.Relationship between nanoscale mineral properties and calcein labeling in mineralizing bone surfaces［J］.Connect Tissue Res，2014，55（sup1）：15-17.
  23. 23.
    YANG X Y，WU D D，ZHUANG C C，et al.Anti-osteoporosis effects of mammalian lignans and their precursors from flaxseed and safflower seed using zebrafish model［J］.J Food Sci，2023，88（12）：5278-5290.
  24. 24.
    DING J，YAN R，WANG L，et al.Using alizarin red staining to detect chemically induced bone loss in zebrafish larvae［J］.J Vis Exp，2021（178）：e63251.
  25. 25.
    XIE B，ZHOU H，LIU H，et al.Salidroside alleviates dexamethasone-induced inhibition of bone formation via transforming growth factor-beta/Smad2/3 signaling pathway［J］.Phytother Res，2023，37（5）：1938-1950.
  26. 26.
    STUDDERT J B，BILDSOE H，MASAMSETTI V P，et al.Visualization of the cartilage and bone elements in the craniofacial structures by alcian blue and alizarin red staining［J］.Methods Mol Biol，2022，2403：43-50.
  27. 27.
    MEAD T J.Alizarin red and alcian blue preparations to visualize the skeleton［J］.Methods Mol Biol，2020，2043：207-212.
  28. 28.
    BELER M，ÜNAL İ，CANSIZ D，et al.Alcian blue staining for chondrocranium development in zebrafish［J］.Methods Mol Biol，2024：447-457.
  29. 29.
    TAYLOR S C，NADEAU K，ABBASI M，et al.The ultimate qPCR experiment：Producing publication quality，reproducible data the first time［J］.Trends Biotechnol，2019，37（7）：761-774.
  30. 30.
    WANG Y L，LI J，LIU L，et al.Biomechanopharmacological study of Panax notoginseng saponins on high shear-induced platelet aggregation and thrombosis［J］.Chin J Exp Tradit Med Form，2024，30（23）：111-120.
  31. 31.
    ZUO Y，CHEN C，LIU F，et al.Pinoresinol diglucoside mitigates dexamethasone-induced osteoporosis and chondrodysplasia in zebrafish［J］.Toxicol Appl Pharmacol，2024，484：116884.
  32. 32.
    CAI Z，WANG H，JIANG J，et al.Elaborate the mechanism of ancient classic prescriptions （Erzhi formula） in reversing GIOP by network pharmacology coupled with zebrafish verification［J］.Evid Based Complement Alternat Med，2022，2022（1）：7019792.
  33. 33.
    KIM Y，BRODT M D，TANG S Y，et al.MicroCT for scanning and analysis of mouse bones［J］.Methods Mol Biol，2021，2230：169-198.
  34. 34.
    NGUYEN S V，LANNI D，XU Y，et al.Dynamics of the zebrafish skeleton in three dimensions during juvenile and adult development［J］.Front Physiol，2022，13：875866.
  35. 35.
    JIANG Z，DENG L，LI M，et al.Ginsenoside Rg1 modulates PI3K/Akt pathway for enhanced osteogenesis via GPER［J］.Phytomedicine，2024，124：155284.
  36. 36.
    PAN X，YU H，SHI X，et al.Characterization of flow direction in microchannels and zebrafish blood vessels by scanning fluorescence correlation spectroscopy［J］.J Biomed Opt，2007，12（1）：014034.
  37. 37.
    HAYAT S，MAGREY M N.Glucocorticoid-induced osteoporosis：Insights for the clinician［J］.Cleve Clin J Med，2020，87（7）：417-426.
  38. 38.
    BOHNS F R，SHIH Y R，CHUANG Y J，et al.Influence of prednisolone and alendronate on the de novo mineralization of zebrafish caudal fin［J］.JBMR Plus，2021，5（2）：e10435.
  39. 39.
    CARVALHO F R，FERNANDES A R，CANCELA M L，et al.Improved regeneration and de novo bone formation in a diabetic zebrafish model treated with paricalcitol and cinacalcet［J］.Wound Repair Regen，2017，25（3）：432-442.
  40. 40.
    SIMãO M，GAVAIA P J，CAMACHO A，et al.Intracellular iron uptake is favored in Hfe-KO mouse primary chondrocytes mimicking an osteoarthritis-related phenotype［J］.Biofactors，2019，45（4）：583-597.
  41. 41.
    BO L，LIU Z，ZHONG Y，et al.Iron deficiency anemia's effect on bone formation in zebrafish mutant［J］.Biochem Biophys Res Commun，2016，475（3）：271-276.
  42. 42.
    GUO G Y，XING T，LI X Z，et al.Research progress on Taohong Siwu Decoction in the treatment of osteonecrosis of the femoral head［J］.Mod Tradit Chin Med，2024，44（3）：1-6.
  43. 43.
    ZHAO R，JIANG J，XIAO S C，et al.Study on Taohong Siwu decoction reversing glucocorticoid-induced osteoporosis in zebrafish model［J］.Acta Pharm Sin，2019，54（2）：313-320.
  44. 44.
    XIONG X，YANG M，HAI Z，et al.Maternal Kdm2a-mediated PI3K/Akt signaling and E-cadherin stimulate the morula-to-blastocyst transition revealing crucial roles in early embryonic development［J］.Theriogenology，2023，209：60-75.
  45. 45.
    NA N，ZHAO D，ZHANG J，et al.Carbamylated erythropoietin regulates immune responses and promotes long-term kidney allograft survival through activation of PI3K/Akt signaling［J］.Signal Transduct Target Ther，2020，5（1）：194.
  46. 46.
    LYU G Y，YAN M Q，CHEN S H.Research progress on pharmacological effects related to the efficacy of Dendrobium officinale［J］.China J Chin Mater Med，2013，38（4）：489-493.
  47. 47.
    LIU S，PI J，ZHANG Q.Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway［J］.Redox Biol，2022，54：102389.
  48. 48.
    CAI X J，HUANG M Y，DING A W，et al. Research progress on the origin and pharmacological effects of Erzhi pill［J］.Chin J Exp Tradit Med Form，2011，17（23）：272-275.
  49. 49.
    ZHONG Z，LI Y，CHEN Y，et al.Predicting and exploring the mechanisms of Erzhi pill in prevention and tre atment of osteoporosis based on network pharmacology and zebrafish experiments［J］.Drug Des Devel Ther，2021，15：817-827.
  50. 50.
    GAO J，LYU S W.Research progress on chemical constituents and pharmacological effects of ginseng［J］.Guid J Tradit Chin Med Pharm，2021，27（1）：127-130，137.
  51. 51.
    龙宇，向燕，谭裕君，等.黄芩苷药理作用及新剂型的研究进展［J］.中草药，2019，50（24）：6142-6148.
  52. 52.
    ZHAO Y，WANG H L，LI T T，et al.Baicalin ameliorates dexamethasone-induced osteoporosis by regulation of the RANK/RANKL/OPG signaling pathway［J］.Drug Des Devel Ther，2020，14：195-206.
  53. 53.
    CHEN X，WANG Z，DUAN N，et al.Osteoblast-osteoclast interactions［J］.Connect Tissue Res，2018，59（2）：99-107.
  54. 54.
    MONTALCINI T，ROMEO S，FERRO Y，et al.Osteoporosis in chronic inflammatory disease：The role of malnutrition［J］.Endocrine，2013，43（1）：59-64.
  55. 55.
    LEWIECKI E M.Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis［J］.Drug Healthc Patient Saf，2011，3：79-91.
  56. 56.
    LIAN C，WU Z，GAO B，et al.Melatonin reversed tumor necrosis factor‐alpha‐inhibited osteogenesis of human mesenchymal stem cells by stabilizing Smad 1 protein［J］.J Pineal Res，2016，61（3）：317-327.
  57. 57.
    SHARAN K，LEWIS K，FURUKAWA T，et al.Regulation of bone mass through pineal‐derived melatonin-MT 2 receptor pathway［J］.J Pineal Res，2017，63（2）：e12423.
  58. 58.
    LI T，JIANG S，LU C，et al.Melatonin：Another avenue for treating osteoporosis［J］.J Pineal Res，2019，66（2）：e12548.
  59. 59.
    ZHANG Y，LI J，WANG Y，et al.Taxonomy of Epimedium （Berberidaceae） with special reference to Chinese species［J］.Chin Herb Med，2022，14（1）：20-35.
  60. 60.
    WANG H J，QIAO C，ZHAO R，et al.Mechanism study of cycloicaritin reversing glucocorticoid-induced osteoporosis［J］.J Nanjing Univ Tradit Chin Med，2019，35（6）：708-713.
  61. 61.
    LIU Y，YAO J H，MEI Y，et al.Study on chemical constituents of Rhodiola rosea［J］.Chin Tradit Herb Drugs，2024，55（9）：2875-2886.
  62. 62.
    SUN B，WU H，LU J，et al.Irisin reduces bone fracture by facilitating osteogenesis and antagonizing TGF-β/Smad signaling in a growing mouse model of osteogenesis imperfecta［J］.J Orthop Translat，2023，38：175-189.
  63. 63.
    LIU X K，WANG H Y，LIU Y，et al.Research progress on modern pharmacology of evodiamine［J］.Chin Arch Tradit Chin Med，2019，37（4）：860-863.
  64. 64.
    SONG Z，CHEN W，ATHAVALE D，et al.Osteopontin takes center stage in chronic liver disease［J］.Hepatology，2021，73（4）：1594-1608.
  65. 65.
    MARTÍN-MÁRQUEZ B T，SANDOVAL-GARCÍA F，CORONA-MERAZ F I，et al.Osteopontin：A bone-derived protein involved in rheumatoid arthritis and osteoarthritis immunopathology［J］.Biomolecules，2023，13（3）：502.
  66. 66.
    XU P，LIN B，DENG X，et al.Anti-osteoporosis effects of Anemarrhenae Rhizoma/Phellodendri Chinensis Cortex herb pair and its major active components in diabetic rats and zebrafish［J］.J Ethnopharmacol，2022，293：115269.
  67. 67.
    LI Y Q，CHEN Y，FANG J Y，et al.Integrated network pharmacology and zebrafish model to investigate dual-effects components of Cistanche tubulosa for treating both osteoporosis and Alzheimer's disease［J］.J Ethnopharmacol，2020，254：112764.
  68. 68.
    NIU M Y，DONG W T，QIU S M，et al.Research progress on the mechanism of miRNA intervention in osteoporosis and the intervention effect of traditional Chinese medicine［J］.Chin J Exp Tradit Med Form，2024，30（9）：228-235.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website